Verona Pharma

VRNA | NASDAQ | 1 Followers
$105.91 +0.03% $0.03
Follow
Overview Metrics Financials
Loading...

Fair Price

$79.65
Overvalued by 98.2%
To display the fair price of a share, you need to be a member of Bulios Black.

Profile

Verona Pharma is a UK-based biotechnology company specializing in the development of drugs targeting respiratory diseases, particularly chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company is focused on developing innovative therapeutic options aimed at improving lung function and reducing inflammation in the airways. Verona Pharma concentrates on researching and developing medicines that can improve the quality of life for patients suffering from these chronic respiratory conditions.

Feed

1M
Read More

💊 Acquisition of Verona Pharma for 10 billion USD!
Pharmaceutical giant Merck $MRK is expanding its portfolio as it announced the acquisition of Verona Pharma $VRNA, a British company specializing in the treatment of chronic lung disease (COPD). The value of the acquisition is expected to reach approximately $10 billion. This is the company's largest transaction since 2023 a...
Read more
4
Share
Zobrazit další komentáře

The company doesn't have much cash and I don't like the fundamentals either.
Like 0
Don't have an account? Join us

Log in to Bulios

Continue with Google
Continue with Apple
Continue with Facebook
Or use email and password
Reset password
Already a member? Log in

Create Bulios profile

Continue with
Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools
Menu StockBot
Tracker
Upgrade